Subscribe for a Year Subscribe for 3 Months

More than one reader? See corporate license details.

TR Subscribers Get …

  • The best news roundup around. Save some of your valuable time and relax with my Frontpoints week in review. You won’t miss the most important news, deals, and shenanigans–with a dash of context and commentary. Frontpoints runs Fridays. Sample headlines here, here, and here.
  • In-depth, original reports on the scientific, medical, financial & political aspects of industry, from an integrative thinker with 15 years covering the industry. Reports run regularly. Sample headlines here, here, and here.
  • Exclusive commentary from insightful guest writers.
  • No ads. I don’t accept advertising. TR is designed to serve readers, not advertisers. I won’t sell your data, won’t violate your privacy, won’t waste your time, and won’t create click-bait. 
  • Elite company. TR subscribers are biotech’s leading thinkers and doers. 
  • Your next partner, next investment, or next job. That’s what readers are saying; see more here.

Subscriptions for individuals are $149 per year. That’s an unbeatable deal. Or, try out Timmerman Report: Get 3 months for $50.

Subscribe for a Year Subscribe for 3 Months

Corporate & University site licenses

Companies can get a 10% discount off the regular rate of $149 per person per year by purchasing a group of subscriptions. Deeper discounts are available for universities. Get one easy payment and one shared login. E-mail me at luke@timmermanreport.com to subscribe.

Pricing:

Company sizeEstimated # of readersPrice
50 employees or less5$670
50-500 employees15$2,000
Mid-to-Large Companies20+Customized, based on readership

NOTE: Individual subscriptions cannot be shared; that is a copyright violation. By purchasing a corporate license, you obtain the right to share Timmerman Report content internally — not with anyone outside your company. Group subscribers may request PDF reprints of articles for internal posting.

Set up a group corporate subscription: email luke@timmermanreport.com.